12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alpharadin radium-223 regulatory update

Bayer's Bayer HealthCare Pharmaceuticals Inc. business said FDA granted Fast Track designation for Alpharadin radium-223 to treat castration-resistant prostate cancer (CRPC)...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >